Rohan Shah, Manesh R.
Bridget Paravattil, Hazem Elewa. Venkat Vuddanda, Mohit K. CrossRef Alexander G.
Which One Works Best?
I am a healthcare professional in the U. Kareem Bedeir, David R. J Am Coll Cardiol.
Our results suggested that if physicians and patients relied on predicted bleeding rates based on data from the trial, they might substantially underestimate bleeding risk. Practical Cardiovascular Medicine, Atrial Fibrillation and Percutaneous Coronary Intervention, Subgroup Analyses In the comparison of apixaban and warfarin, the main findings were broadly consistent in all subgroup analyses.
Fernanda BellolioRobert D. Obamiro, Leanne Chalmers, Luke R.
Bruce Stambler, Fernando Scazzuso. Such information may not be available in any form in the US medical record or pharmacy data. Lip, Torben Bjerregaard Larsen.
Jaffer, Annabelle Santos Volgman. Effectiveness Outcomes Apixaban was associated with reduced risk of stroke or systemic embolism compared with warfarin hazard ratio [HR] 0. N OACnon—vitamin K oral anticoagulant. Lastly, it should be noted that non-steroidal anti-inflammatory drugs NSAIDS - such as ibuprofen and similar agents - as well as other antiplatelet agents such as clopidogrel and other anticoagulants can increase the bleeding risk with dabigatran without changing the blood level of the drug.
A matter of time?.
Speak to a live representative:
CrossRef 41 Timothy A. Michael Buerke, Hans-Martin Hoffmeister. A proportional hazards model for the subdistribution of a competing risk.
A tool for assessing the feasibility of comparative effectiveness research.
A pharmacogenetic review of newer antiplatelets clopidogrel, prasugrel and ticagrelor and anticoagulants dabigatran, rivaroxaban, apixaban and edoxaban. American Heart Journal Linking to any other site is at your own risk.